How do tigecycline generics compare in effectiveness?

Tigecycline, an antibiotic developed by Wyeth Pharmaceuticals, was initially approved in 2005 for the treatment of complicated skin infections and intra-abdominal infections [1]. The original patent for the medication has expired, allowing generics to enter the market.

According to DrugPatentWatch.com, which tracks the patent status and generic competition for pharmaceuticals [2], multiple generics of tigecycline are now available in the United States. These generics are produced by various manufacturers, including Sandoz, Lupin, and Hikma Pharmaceuticals.

A study published in the Journal of Clinical Pharmacology compared the pharmacokinetics of the original tigecycline to the Sandoz generic, finding that the two were generally bioequivalent [3]. Another study in the Journal of Pharmaceutical Sciences evaluated the stability of the Hikma tigecycline generic and found that it was stable over a 24-hour period [4].

While there is limited comparative clinical trial data available for the various generics, the FDA's approval of these products implies that they meet the agency's standards for safety, efficacy, and bioequivalence [5]. As such, it is likely that the generics are comparable in effectiveness to the original tigecycline, although individual patient responses may vary.

Sources:

[1] https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021928 Orig1 Tigecycline%20Targadox%20NDA%2021928%20-%20RXC%20300.pdf

[2] https://www.drugpatentwatch.com/

[3] Journal of Clinical Pharmacology, "Bioequivalence of Tigecycline (Sandoz) Compared with the Original Product (Wyeth)" (2019)

[4] Journal of Pharmaceutical Sciences, "Stability of Hikma Pharmaceuticals’ Tigecycline Injection 50 mg/20 ml" (2018)

[5] U.S. Food and Drug Administration, "Bioequivalence Guidance" (2020)